Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Name

Click to order products ascending

Display 15 Products per page

US Image-Guided Surgical Neuronavigation and EBRT Systems Market

$3,750.00

The US image-guided surgical (IGS) neuronavigation and external beam radiation therapy (EBRT) systems market totaled more than $284m in 2015.
October 31, 2016
Find out more
US Neurointerventional Devices Market

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain. Neurointerventional devices, which contributed sales of more than $870m in the US in 2015, involve a variety of standard and application-specific transcatheter tools and techniques for the treatment of cerebrovascular pathologies (such as aneurysms, arteriovenous malformations [AVMs], and acute and chronic thromboembolic and atherosclerotic occlusions) that prompt clinically significant distortions of cerebral blood flow and carry a high risk of catastrophic breakdowns of cerebrovascular circulation manifested by hemorrhagic or ischemic stroke.
September 21, 2016
Find out more
US Neurointerventional Devices Market, September 2016

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.
September 21, 2016
Find out more
US Pricing and Reimbursement

$2,995.00

Historically, few pricing controls have been implemented in the US; however, there is greater pressure to implement controls to help contain costs associated with the expansion of public healthcare provision.
November 2, 2016
Find out more
US Regulatory Issues

$2,995.00

Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.
November 2, 2016
Find out more
Utibron Neohaler
Read More
Novartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol and glycopyrrolate.
July 31, 2018
Find out more
V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
V180
Read More
Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241).
January 4, 2018
Find out more
Vaccines Market Access in Emerging Markets

$3,000.00

Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.
August 29, 2019
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more
Value-Based Pricing – Evolution Rather Than Revolution

$5,000.00

A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.
November 4, 2016
Find out more
Vargatef
Read More
Boehringer Ingelheim will hope to increase Vargatef’s (nintedanib) market share at second-line despite

rising competition in this setting.
August 30, 2016
Find out more
Vascepa
Read More
Vascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
November 20, 2019
Find out more
Vasotec
Read More
Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

competition from generic equivalents.
August 2, 2016
Find out more
VB-111
Read More
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

from the Phase III GLOBE study.
April 13, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *